Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy-Reference-Cited by-同舟云学术

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

Published:2019-03 Issue:3 Volume:14 Page:494-502
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Suresh Karthik,Psoter Kevin J.,Voong Khinh Ranh,Shankar Bairavi,Forde Patrick M.,Ettinger David S.,Marrone Kristen A.,Kelly Ronan J.,Hann Christine L.,Levy Benjamin,Feliciano Josephine L.,Brahmer Julie R.,Feller-Kopman David,Lerner Andrew D.,Lee Hans,Yarmus Lonny,Hales Russell K.,D’Alessio Franco,Danoff Sonye K.,Naidoo Jarushka

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

4. Pneumonitis from anti-PD-1/ PD-L1 therapy;Balaji;Oncol (Williston Park),2017

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

3. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15

4. A Review of Immunotherapy in Non-Small-Cell Lung Cancer;Current Oncology;2024-06-17

5. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC;BMC Pulmonary Medicine;2024-05-23